The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

The Obesity Gurukul initiative will train over 20,000 healthcare professionals across India through a hybrid education model ...

Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for May 1.

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug's blockbuster potential in the company's ...

The race for oral GLP-1 weight loss drugs is intense. Pfizer drops a candidate, Eli Lilly shows progress, and Novo Nordisk seeks FDA approval for oral Wegovy.

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral obesity drug. Click for my LLY update.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.